Ashley Gallagher, Editor

These mothers are approximately 17% less likely to die from cardiovascular disease, 14% less likely to develop coronary heart disease, and 12% less likely to suffer a stroke, the data show.

Compensation was a positive, while workload, management, and lack of work/life balance are the top reasons for dissatisfaction.

Ensovibep has met the primary endpoint of viral load reduction over 8 days in a phase 2 study, the companies said.

More aggressive competition and uptake could cause larger cuts, estimated at up to $124.5 billion between 2021 and 2025, according to the results of a RAND corporation analysis.

Analysis examines the impacted of expected trends in exposure to high blood sugar, low education levels, obesity, and smoking.

Although fewer than 1 in 5 adults with type 2 diabetes are meeting targets to reduce heart disease risk, available therapies can help when combined with new approaches that barriers to care.

A single shot protects for up to 6 months against breakthrough infections, hospitalizations, and intensive care unit admissions, Johnson & Johnson says.

Daridorexant (Quviviq, Idorsia Pharmaceuticals) is indicated for adults who experience difficulties with sleep onset and/or sleep maintenance.

About 48% of individuals experienced a complete or partial response when treated with pembrolizumab, and about two-thirds also had a response that lasted more than 3 years.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

Despite best practice recommendations, prescriptions for acute pharyngitis are frequently not accompanied by testing, Epic Research data show.

Study results establish LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

Results of an analysis from the University of Eastern Finland show that supplementation for 5 years had no effect on total mortality or the incidence of these diseases in older individuals.

The recommendations include full immunization, including third doses and/or any approved boosters.

Proof-of-contest is inexpensive and quantifies specific antigens from a drop of blood within minutes.

GeneSight Mental Health Monitor finds that many struggle to know the difference between teenage behavior and a mental health challenge.

Results of a separate analysis demonstrate that Johnson & Johnson’s booster generated a 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against omicron.

The drug is made from Ananda’s Liquid Structure technology that creates new potential for cannabidiol therapeutics, such as facilitating voluntary opioid sparing.

In the first quarter of 2022, Genprex expects to initiate its Acclaim-2 clinical trial to evaluate the treatment for individuals with histologically confirmed unresectable stage III or IV non–small cell lung cancer.

Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.

The results of an analysis from investigators from Baylor College of Medicine suggest that supplementation with GlyNAC might be beneficial to those who have the virus.

Telisotuzumab vedotin (Teliso-V, AbbVie) is an investigational antibody-drug conjugate that targets c-Met, a receptor tyrosine kinase that is overexpressed in tumors.

Eli Lilly says the drug in combination with TCS also achieved all key secondary endpoints versus the placebo for individuals with AD.

Results from a study conducted by the Institute for Health Metrics and Evaluation show that new cases jumped 26.3% over the same period.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

Individuals receiving the therapy had an 87% reduction in risk for the composite primary endpoint of virus-related hospitalization or all-cause death by day 28.

The therapeutic is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022.

The approval is based on efficacy and safety data from 2 positive phase 3 studies that evaluated a combined study population of 166 individuals, which represented the US population with Cushing syndrome.

Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most often for patients.